Genome synthesis, assembly, and rebooting of therapeutically useful high G+C% mycobacteriophages

C Ching-Chung Ko (Department of Biological Sciences, University of Pittsburgh) A Andrew P. Sikkema (Research Department, Applied Molecular Biology, New England Biolabs) M Michael J. Lauer (Department of Biological Sciences, University of Pittsburgh) E Elizabeth D. Amarh (Department of Biological Sciences, University of Pittsburgh) R Rebecca A. Garlena (Department of Biological Sciences, University of Pittsburgh) D Daniel A. Russell (Department of Biological Sciences, University of Pittsburgh) N Nicole Chew (Ansa Biotechnologies) T Tan Li I Isa Madrigal Harrison (Ansa Biotechnologies) J Jared Ellefson (Ansa Biotechnologies) G Graham F. Hatfull (Department of Biological Sciences, University of Pittsburgh) G Gregory J. S. Lohman (Research Department, Applied Molecular Biology, New England Biolabs)

Abstract

Bacteriophages show therapeutic promise for treating bacterial pathogens including nontuberculous mycobacteria (NTM). A major impediment is the paucity of therapeutically useful phages and the great variation in the phage infection profiles, especially among Mycobacterium abscessus clinical isolates. These limitations—together with the abundance of mycobacteriophage genes of unknown function—could be addressed by synthetic genetic construction of viruses in which undesirable genes can be eliminated and genetic payloads can be readily added. However, the relatively high G+C% content of mycobacteriophage genomes (64.1%) can be challenging for DNA synthesis using phosphoramidite chemistry, and the genomes are relatively large (40 to 150 kbp) for assembly and rebooting in a bacterial host. Here, we demonstrate efficient de novo synthesis of high G+C% DNA fragments using terminal deoxynucleotidyl transferase chemistry, the reconstruction of complete mycobacteriophage genomes using High-Complexity Golden Gate Assembly, and efficient rebooting via electroporation into Mycobacterium smegmatis . Using this approach, we synthesized the genomes of phages BPs (41.9 kbp, 66.6% G+C%) and Bxb1 (50.5 kbp, 63.6% G+C%), and constructed variants carrying targeted mutations or added payloads. Synthetic construction of mycobacteriophages and their derivatives expands the phage repertoire for therapeutic development and provides versatile tools for advancing mycobacterial genetics and phage-based clinical applications.

Article Details

Volume / Issue Vol. 122, Issue 46
Published November 18, 2025
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (12)

C

Ching-Chung Ko

Department of Biological Sciences, University of Pittsburgh

A

Andrew P. Sikkema

Research Department, Applied Molecular Biology, New England Biolabs

M

Michael J. Lauer

Department of Biological Sciences, University of Pittsburgh

E

Elizabeth D. Amarh

Department of Biological Sciences, University of Pittsburgh

R

Rebecca A. Garlena

Department of Biological Sciences, University of Pittsburgh

D

Daniel A. Russell

Department of Biological Sciences, University of Pittsburgh

N

Nicole Chew

Ansa Biotechnologies

T

Tan Li

I

Isa Madrigal Harrison

Ansa Biotechnologies

J

Jared Ellefson

Ansa Biotechnologies

G

Graham F. Hatfull

Department of Biological Sciences, University of Pittsburgh

G

Gregory J. S. Lohman

Research Department, Applied Molecular Biology, New England Biolabs